| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular & Cellular Proteomics 3:379-398, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.
,
,¶,
From the Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208; Division of Molecular Medicine, Millennium Pharmaceuticals, Inc., Cambridge, MA 01238; || Department of Pathology, Brigham Women’s Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115; ** US Labs, Inc., 2601 Campus Drive, Irvine, CA 92612; Department of Medicine, Washington University, St. Louis, MO 63110; Departments of Medicine and Pathology, MD Anderson Cancer Center, Houston, TX 77030
The HER-2/neu oncogene, a member of the epidermal growth factor receptor or erb gene family, encodes a transmembrane tyrosine kinase receptor that has been linked to prognosis and response to therapy with the anti-HER-2-humanized monoclonal antibody, trastuzumab (Herceptin, Genentech, South San Francisco, CA) in patients with advanced metastatic breast cancer. HER-2/neu status has also been tested for its ability to predict the response of breast cancer to other therapies including hormonal therapies, topoisomerase inhibitors, and anthracyclines. This review includes an analysis of 80 published studies encompassing more than 25,000 patients designed to consider the relative advantages and disadvantages of the various methods of measuring HER-2/neu in clinical breast cancer specimens. Southern blotting, PCR amplification detection, and fluorescence in situ hybridization assays designed to detect HER-2/neu gene amplification are compared with HER-2/neu protein overexpression assays performed by immunohistochemical techniques applied to frozen and paraffin-embedded tissues and enzyme immunoassays performed on tumor cytosols. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The role of HER-2/neu testing for the prediction of response to trastuzumab therapy in breast cancer is reviewed along with the current studies designed to test whether HER-2/neu status can predict the response to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation. The review will also evaluate the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R A Walker, J M S Bartlett, M Dowsett, I O Ellis, A M Hanby, B Jasani, K Miller, and S E Pinder HER2 testing in the UK: further update to recommendations J. Clin. Pathol., July 1, 2008; 61(7): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Walker Immunohistochemical markers as predictive tools for breast cancer J. Clin. Pathol., June 1, 2008; 61(6): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Hofmann, O Stoss, T Gaiser, H Kneitz, P Heinmoller, T Gutjahr, M Kaufmann, T Henkel, and J Ruschoff Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy J. Clin. Pathol., January 1, 2008; 61(1): 89 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rauser, R. Weis, H. Braselmann, M. Feith, H. J. Stein, R. Langer, P. Hutzler, M. Hausmann, S. Lassmann, J. R. Siewert, et al. Significance of HER2 Low-Level Copy Gain in Barrett's Cancer: Implications for Fluorescence In situ Hybridization Testing in Tissues Clin. Cancer Res., September 1, 2007; 13(17): 5115 - 5123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. F. Pirollo, A. Rait, Q. Zhou, S. H. Hwang, J. A. Dagata, G. Zon, R. I. Hogrefe, G. Palchik, and E. H. Chang Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System Cancer Res., April 1, 2007; 67(7): 2938 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meng, D. Tripathy, S. Shete, R. Ashfaq, H. Saboorian, B. Haley, E. Frenkel, D. Euhus, M. Leitch, C. Osborne, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues PNAS, November 14, 2006; 103(46): 17361 - 17365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jackisch HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy Oncologist, September 1, 2006; 11(suppl_1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Maqani, A. Belkhiri, C. Moskaluk, S. Knuutila, A. A. Dar, and W. El-Rifai Molecular Dissection of 17q12 Amplicon in Upper Gastrointestinal Adenocarcinomas Mol. Cancer Res., July 1, 2006; 4(7): 449 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Singhal, Y. C. Awasthi, and S. Awasthi Regression of Melanoma in a Murine Model by RLIP76 Depletion Cancer Res., February 15, 2006; 66(4): 2354 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Kim, X. Cui, S. G. Hilsenbeck, and A. V. Lee Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer Clin. Cancer Res., February 1, 2006; 12(3): 1013s - 1018s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Bates and T. Fojo Epidermal Growth Factor Receptor Inhibitors: A Moving Target? Clin. Cancer Res., October 15, 2005; 11(20): 7203 - 7205. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish International Journal of Surgical Pathology, October 1, 2005; 13(4): 343 - 351. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |
